Previous close | 38.73 |
Open | 37.10 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 37.01 - 37.10 |
52-week range | 37.01 - 37.10 |
Volume | |
Avg. volume | N/A |
Market cap | 8.844B |
Beta (5Y monthly) | 0.87 |
PE ratio (TTM) | 19.46 |
EPS (TTM) | 1.90 |
Earnings date | 28 Feb 2022 - 04 Mar 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Moderna (NASDAQ: MRNA) is having a terrific year, raking in profits and generating plenty of cash due to its COVID-19 vaccine. As its business grows and the company plans for a post-COVID future, it needs to make smart decisions with its money. On May 9, Jorge Gomez was set to become Moderna's CFO, replacing David Meline, who is planning to retire.
(Bloomberg) -- Moderna Inc. said it acted immediately to remove Jorge Gomez as chief financial officer earlier this week after it learned of an investigation related to the handling of incentives at his former company. Most Read from Bloomberg$11 Trillion and Counting: Global Stock Slump May Not Be OverWhereabouts of Terra’s Bitcoin Reserve a Mystery After TransfersTerra Hasn’t Killed Crypto, But It Was a Narrow EscapeCathie Wood Just Keeps Buying Coinbase and Getting More InflowsGoldman’s Blank
A top executive at a leading Covid vaccine manufacturer earned $700,000 in just one day after he quit abruptly amid an investigation at his former employer.